Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 77Observational 18Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Carcinoma, Renal Cell 7Pancreatic Neoplasms 6Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Sarcoma 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 3Melanoma 3Stomach Neoplasms 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Head and Neck Neoplasms 2Glioblastoma 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Wilms Tumor 1Urologic Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Prostatic Diseases 1

Interventions

Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Urogenital Neoplasms × Genitourinary × Clear all
NCT01217697 2017-03-24

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved for marketing
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡